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control score on inequalities in smoking
prevalence and premature coronary heart
disease mortality: a modelling study
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Abstract
Background: Smoking is more than twice as common among the most disadvantaged socioeconomic groups
in England compared to the most affluent and is a major contributor to health-related inequalities. The
United Kingdom (UK) has comprehensive smoking policies in place: regular tax increases; public information
campaigns; on-pack pictorial health warnings; advertising bans; cessation; and smoke-free areas. This is
confirmed from its high Tobacco Control Scale (TCS) score, an expert-developed instrument for assessing the
strength of tobacco control policies. However, room remains for improvement in tobacco control policies.
Our aim was to evaluate the cumulative effect on smoking prevalence of improving all TCS components in
England, stratified by socioeconomic circumstance.
Methods: Effect sizes and socioeconomic gradients for all six types of smoking policy in the UK setting were
adapted from systematic reviews, or if not available, from primary studies.
We used the IMPACT Policy Model to link predicted changes in smoking prevalence to changes in premature
coronary heart disease (CHD) mortality for ages 35–74. Health outcomes with a time horizon of 2025 were
stratified by quintiles of socioeconomic circumstance.
Results: The model estimated that improving all smoking policies to achieve a maximum score on the TCS
might reduce smoking prevalence in England by 3 % (95 % Confidence Interval (CI): 1–4 %), from 20 to 17 %
in absolute terms, or by 15 % in relative terms (95 % CI: 7–21 %). The most deprived quintile would benefit
more, with absolute reductions from 31 to 25 %, or a 6 % reduction (95 % CI: 2–7 %).
There would be some 3300 (95 % CI: 2200–4700) fewer premature CHD deaths between 2015–2025, a 2 % (95 % CI:
1.4–2.9 %) reduction. The most disadvantaged quintile would benefit more, reducing absolute inequality of CHD
mortality by about 4 % (95 % CI: 3–9 %).
Conclusions: Further, feasible improvements in tobacco control policy could substantially improve population health,
and reduce health-related inequalities in England.
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Socioeconomic inequalities
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Background
Smoking remains common in England, with 19 % of adults
aged 16 and over reported as smokers in 2013 [1]. This
prevalence changed slightly from 21 % in 2007 [2]. Further-
more, large differences in smoking prevalence persist across
socioeconomic groups; over 30 % of people with routine
and manual jobs smoke, compared to less than 15 % of
those in managerial and professional occupations [2, 3].
Smoking explains more than one-quarter of the socioeco-
nomic gradient in total mortality in Great Britain [4].
In 2013, smoking caused an estimated 80,000 deaths in
England among adults aged 35 and over. This amounts to
17 % of all deaths for these ages, unchanged since 2005.
Over 450,000 hospital admissions were attributable to
smoking, representing 4 % of all adult admissions [5].
These numbers may underestimate the true burden of
smoking, as a recent study has expanded the list of dis-
eases linked to smoking [6].
Circulatory diseases alone represent 17,300 (13 %) deaths
and 134,000 (19 %) hospital admissions [2]. Coronary heart
disease (CHD) has the highest number of smoking attribut-
able deaths (7900) among circulatory diseases and the third
highest number overall, after lung cancer and chronic ob-
structive pulmonary disease [2].
The United Kingdom (UK) has strong tobacco control
policies compared to many European peers, achieving
the highest score on the Tobacco Control Scale (TCS)
(74 out of 100) among 34 European countries [7]. The
TCS is an expert-developed instrument for assessing the
strength of tobacco control policies with data compiled
via a survey of national representatives to the European
Network for Smoking and Tobacco Prevention, supple-
mented with data from other data sources (described in
more detail in [7]). The most recent survey took place in
2013 and represents legislation in place as of 1 January
2014, prices as of 1 July 2013, and tobacco control
budget for 2012. The TCS assesses six types of tobacco
control policies; price, public place bans, public informa-
tion campaign spending, advertising bans, health warn-
ings, and treatment, each based on several indicators.
World Health Organization MPOWER rankings for the
UK are reassuringly similar [8].
Systematic reviews have found some evidence of so-
cioeconomic gradients in effectiveness of tobacco con-
trol policies [9–12]. However, with the exception of
taxation, this evidence is limited, mixed and further
complicated by different definitions of socioeconomic
circumstance (e.g. education, occupation, income). Inter-
estingly, evidence suggest that tobacco tax increases are
more effective among the less well-off.
There is a gap in the literature relating socioeconomic
inequalities in effectiveness of tobacco control policies, to
inequalities in health outcomes. In this study, we therefore
evaluated the potential effectiveness of maximising the
TCS score for the UK using a model stratified by socio-
economic circumstance (SEC). We then linked predicted
reductions in smoking prevalence to reductions in prema-
ture CHD mortality in England and assessed changes in
inequality of premature CHD mortality.
Methods
The previously validated, deterministic, cell-based IM-
PACT Policy Model has been used to model the change in
adult smoking prevalence, in England, that might result
from changes in tobacco control policies, and translated
it to CHD deaths using a population attributable risk
fraction approach [13, 14]. The method has been previ-
ously used to analyse health benefits of reduced smok-
ing prevalence in other European countries [15]. The
uncertainty was estimated using probabilistic sensitivity
analysis in a Monte Carlo approach (please refer to the
Additional file 1 for a detailed description). Of the four
UK countries, analysis was restricted to England because
smoking prevalence can be directly linked to a health out-
come using a socioeconomic indicator.
Smoking prevalence
Smoking prevalence in 2012 by age, sex, and quintile
groups of Index of Multiple Deprivation (IMDQ) for Eng-
land were published by the Office for National Statistics
(ONS). ONS estimates were extracted from the 2012 Inte-
grated Household Survey, which contains information
from approximately 340,000 individual respondents [16].
We used this smoking prevalence from 2012 as the base-
line from which reductions could occur. Age was summa-
rized into groups: 18–24, 25–34, 35–44, 45–54, 55–64,
65–74, and 75+. We used only the age groups 35–44, 45–
54, 55–64, and 65–74 so as to capture premature adult
CHD deaths. IMDQ is an area-based socioeconomic indi-
cator composed of seven domains of deprivation (income,
employment, health, education, crime, access to services,
living environment), each with around five indicators [17].
Policy scenario
We modelled an increase in each component of the TCS
to raise the overall score to the perceived maximum of
100. This would bring the UK fully in line with currently
accepted best practices.
Changes in smoking prevalence due to policy changes
were adapted primarily from systematic reviews. When
these were not available, we used relevant primary studies
or inputs used in published modelling studies. Table 1
shows the policy types, current UK status, maximum
effect sizes, SEC gradients, and modelling decisions:
Price
TCS ranks average price per pack in the UK as the high-
est in Europe. We modelled a further 20 % increase in
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retail price, equivalent to an increase in excise duty from
approximately 61 to 81 % of the retail price. The rela-
tionship between tax increases and smoking prevalence
(i.e. the elasticities) were based on the British setting,
including a socioeconomic gradient that makes price
increases more effective among those of lower status
[18, 19] (Additional file 1: Table S2). Data from the
United States (US), Australia and Canada suggest the
same relationship between elasticity and socioeconomic
status [20].
Smoke-free public places
The UK scores highly on smoke-free places with the top
score for bars & restaurants, public transport, and work
places. There remains room for improvement in other
public places (e.g. education, health). The relationship be-
tween smoking prevalence and smoke-free places was
based on inputs to other modelling studies [21, 22]. A
systematic review of workplace bans reported higher
effectiveness among those to whom the ban applied [23],
but the population effect would be lower. We assumed a
small additional benefit could be achieved from further
bans in public places not currently covered. We assumed
no SEC gradient because there is mixed evidence [10, 12].
The evidence more strongly supports SEC gradients that
benefit the more affluent for workplace bans [9, 12]; how-
ever, the UK already has strong workplace bans.
Public information campaigns (mass media)
Anti-tobacco campaign spending was the TCS compo-
nent with the most room for improvement due to
funding cuts in 2010 that resulted in large declines in
quit-line calls, anti-smoking literature requests, and
hits to the smoking cessation website [24]. Funding
rebounded somewhat by 2012 [25]. We used the maximum
single-year effect for public information campaigns on
Table 1 UK’s status of tobacco control policies and additional modelled policies to maximise Tobacco Control Scale
Policy type UK status (2013)
[Additional modelled
policies]
Maximum effect on smoking
prevalence
SEC gradient Model decision
Price 27 out of 30 [20 %
retail price increase]
3.5 % reduction for 10 %
price increase [19]
For each 10 % price increase,
prevalence relative decreases
by [18]:
Lowest SEC: 6.3 %
20 % price increase. The
effect on prevalence was
modelled from published
price elasticities by SEC.
Highest SEC: 1.2 %
Smoke-free places 21 out of 22
[Smoking in cars with
minors banned as of
October 2015 and
extend ban to all
public places]
Worksite total ban 6 %
reduction compared to 2 %
for partial ban; Restaurant
total ban 1 % reduction [21,
22]
Smoke-free workplaces generally
favour higher SEC [9, 12]. Mixed
evidence for other types smoke-
free places [10, 12].
Additional 1 % prevalence
relative reduction possible
because little room for
improvement. Assume no
SEC gradient.
Public information
campaigns
3 out of 15 [a five-
fold increase to 2012
government budget
spending media
campaigns]
Maximum annual effect 2 %
[26, 27]
Often favour highest SEC
[28]
Additional 1 % (average)
prevalence relative reduction
possible because moderate
campaigns already in place.
Assume Highest SEC twice
as responsive as Lowest SEC.
Advertising bans 10 out of 13 [Point-of-
sale and display ad
ban in small stores as
of April 2015]
Comprehensive ban 5 %
prevalence reduction; Total
ban 3 % reduction; Weak ban
1 % reduction [21, 29]
No evidence of gradient
[9, 10]
Additional 2 % prevalence
relative reduction possible
Health Warnings
(including plain packaging)
4 out of 10 [Plain
packaging approved
by Parliament, larger
health warnings
(>80 % of the packet)]
Large bold graphic warnings
reduce prevalence by 2 %;
Weaker warnings 1 %
reduction. Plain packaging
has maximum effect similar
to health warnings [33]
No evidence of gradient
[9, 10, 35]
Additional 3 % prevalence
relative reduction possible
(1 % from larger health
warnings and 2 % from plain
packaging).
Treatment 9 out of 10 [Full
reimbursement of
treatment]
4.75 % reduction in
prevalence (no details on
individual components of
treatment policy) [21]
Low SEC may have lower
success, but programs can be
targeted to eliminate gradient
[36]
Additional 0.5 % prevalence
relative reduction possible
because most elements in
place already. No SEC
gradient
SEC denotes Socioeconomic circumstance
UK status for 2013 (2nd column) is based on Tobacco Control Scale [7]
Effect on prevalence, socioeconomic gradient, and parameters used in model for changes in policies. Uncertainty in the policy effect sizes is described in
Additional file 1: Table S1
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smoking prevalence [26, 27]. Then, we assumed that half
of that maximum effect could be achieved after maximiz-
ing the TCS public information campaign component, be-
cause moderate campaigns are already in place. Although
there is some controversy regarding the equity of these in-
terventions, when cessation is considered as the outcome,
their SEC gradient likely favours the more affluent [12, 28].
Advertising bans
The UK has advertising bans in most areas: TV/radio,
cinema, outdoor, print, and sponsorship. Advertising
bans at point of sale and displays were implemented in
April 2015 but were not in the TCS score, nor would
their effect be represented in the smoking prevalence
data due to their recency. Comprehensive advertising
bans could have a maximum effect on consumption of
about 7 % [21, 29]. The maximum effect on prevalence
would be about 5 % if we assume that 70 % of the re-
duction in consumption is due to a reduction in preva-
lence, as typically observed for price increases [19]. We
modelled that the newly implemented components of
advertising bans would result in a 2 % reduction in
prevalence. There is no evidence of SEC gradients in
response to advertising bans [10, 12]. Standardized
packs are also a type of advertising ban in the TCS, and
these are discussed more extensively below.
Health warnings (including plain packaging)
On-pack health warnings in the UK contain a pictorial
warning, but they could be larger. The maximum effect-
iveness of health warnings was based on other modelling
studies [21, 22], which is a fair midpoint between low
estimates of the US Food and Drug administration
(FDA) and high estimates from Canada (discussed in
[30]). There is no evidence of a SEC gradient [9, 10].
Plain packaging is an element of health warnings in the
TCS, and In March 2015, UK Parliament approved plain
packaging to begin in May 2016 [31]. Plain packaging has
been shown to increase quitting intentions and other
quitting-related behaviours among smokers [32]. Follow-
ing implementation of plain packaging in Australia, there
was a doubling in the percent of smokers who notice the
warnings first, and who do not like the look of their packs
[33]. We therefore assumed that plain packaging itself
would be double the maximum effectiveness of health
warnings alone (2 % prevalence reduction only from plain
packaging, on top of additional improvements by increas-
ing the size of current health warnings). Some experts
have predicted about 1 % absolute prevalence reductions
[34], which would correspond to about 5 % relative reduc-
tion. We chose to use the more conservative 2 % relative
reduction due to the uncertainty around the use of expert
elicitation. Support for plain packs in Australia was
observed to have no SEC gradient [35].
Treatment
UK has most treatment elements in place (recording
smoking status, brief advice, quit-line, network cessa-
tion support), and is only lacking full reimbursement.
Maximum effectiveness was based on other modelling
studies [21, 23], and only a small improvement was
assumed possible. Smoking cessation services in England
have produced essentially constant success rates across
SEC [36].
Each policy improvement would result in a propor-
tional decline in smoking prevalence. For example, a
10 % decline from a baseline of 20 % smoking preva-
lence would mean a 2 % absolute decline. The potential
reductions in smoking prevalence for each policy type
are in Table 1. Where policies are known to have a so-
cioeconomic gradient in effectiveness, we modified the
SEC-specific effectiveness accordingly.
Health outcomes
To illustrate health improvement associated with re-
duced smoking prevalence for 2015–2025, we first fore-
casted CHD mortality by 10-year age groups, sex and
IMDQ up to 2025, using a Bayesian age-period-cohort
model [37, 38]. Then, we translated the modelled re-
duction in smoking prevalence into reduction of the
forecasted number of deaths, through a reduction in
the population attributable risk fraction for smoking.
For a more detailed description, please refer to the
Additional file 1. A slow, steady reduction in smoking
prevalence, as was previously observed in England [2],
is considered in our estimations. This is because the
forecast of CHD deaths is based on previous recent
trends of CHD related risk factors, including smoking.
We report premature (ages 35–74) CHD deaths pre-
vented or postponed (DPP) and the associated life years
gained (LYG) for 2015–2025, stratified by sex and
IMDQ.
Results
Improving all smoking policies to maximize the TCS
could reduce overall smoking prevalence in England
from 20 % to approximately 17 % (95 % Confidence
Interval (CI): 16.0–18.7 %). This would represent an ab-
solute decrease of some 3 % and a relative reduction of
approximately 15 % (95 % CI: 7–21 %). Table 2 shows
the adult smoking prevalence for England by IMDQ and
gender, at baseline and with full implementation of the
TCS policies.
The effect would be greatest among the most deprived
quintile, who might achieve an absolute reduction of
approximately 5.8 % (95 % CI: 2.2–6.7 %) and a relative
reduction of 19 % (95 % CI: 7–21 %) (Fig. 1, Table 2). The
reduction would be higher in men (6.4 %; 95 % CI: 2.8–
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6.9 %), because they have higher baseline smoking preva-
lence, than in women (5.3 %; 95 % CI: 2.2–5.8 %).
Taxes might contribute about 48 % (95 % CI: 41–57 %) of
the predicted decline, and this effect could be substantially
larger in the most deprived quintile (68 %). Plain packs
would contribute about 15 % overall (95 % CI: 11–17 %)
(Additional file 1: Table S3).
The model estimated that a total of approximately
3300 (95 % CI: 2200–4700) premature CHD deaths
might be prevented or postponed, about 2 % (95 % CI:
1.4–2.9 %) of all predicted premature CHD deaths from
2015–2025 (Table 2). These deaths prevented or post-
poned would lead to approximately 52,000 LYG (95 %
CI: 35,000–76,000). Due to their higher smoking preva-
lence and higher CHD mortality, the most deprived
quintile should benefit more, resulting in an absolute
inequality reduction of some 1000 (95 % CI: 700–2200)
premature CHD deaths. The most deprived quintile
would also gain the most life years (19,000; 95 % CI:
13,000–29,000). Even if there is no SEC gradient in the
tax policy effect (Additional file 1: Table S4), the benefits
would still favour the most disadvantaged groups, but
the results would not be as strong.
Among men, most (about two-thirds) of the life
years gained would be in the age groups 45–54 and
55–64. The remainder would be about evenly split
Table 2 Smoking prevalence at baseline (2012 ONS data) and with all Tobacco Control Scale policies maximised
IMDQ Sex Smoking prevalence Premature CHD deaths Life years gained
Baseline With policies 95 % CI Relative Reduction 95 % CI Baseline Reduction 95 % CI 95 % CI
1 Men 13.1 % 11.8 % (10.4–12.4 %) 10 % (6–20 %) 16100 180 (130–280) 2800 (2000–4300)
2 Men 16.7 % 14.7 % (13.3–15.5 %) 12 % (7–20 %) 20900 290 (210–390) 4500 (3300–6100)
3 Men 21.1 % 18.2 % (16.9–19.5 %) 14 % (7–20 %) 25300 440 (310–620) 6700 (4800–9500)
4 Men 25.6 % 21.8 % (20.3–23.5 %) 15 % (8–20 %) 28700 630 (440–900) 9300 (6600–13300)
5 Men 34.3 % 27.9 % (27.0–31.8 %) 19 % (7–21 %) 32600 900 (610–1220) 12800 (8800–17200)
1 Women 10.2 % 9.2 % (8.1–9.6 %) 10 % (6–20 %) 4100 50 (30–80) 900 (600–1400)
2 Women 13.5 % 11.9 % (10.8–12.6 %) 12 % (7–20 %) 5300 80 (60–110) 1400 (1000–2000)
3 Women 17.0 % 14.6 % (13.6–15.7 %) 14 % (7–20 %) 6900 130 (80–190) 2300 (1500–3500)
4 Women 21.4 % 18.2 % (17.0–19.7 %) 15 % (8–20 %) 10300 250 (150–400) 4300 (2700–7100)
5 Women 28.3 % 23.0 % (22.2–26.2 %) 19 % (7–21 %) 12500 370 (210–680) 6500 (3700–11900)
Premature (ages 35–74) coronary heart disease (CHD) deaths and reduction with policies implemented, aggregate on 2015–2025. Calculations are described in
Additional file 1. 95 % confidence intervals (CI) from probabilistic sensitivity analysis of key parameters. Results stratified by sex and quintile groups of Index of
Multiple Deprivation (IMDQ, 1 = least deprived, 5 =most deprived)
Fig. 1 Observed vs. estimated smoking prevalence after maximising the Tobacco Control Scale. Stratified by quintiles of Index of Multiple Deprivation
(IMDQ), for ages 35–74, England. Average smoking prevalence for IMDQ is a weighted average across ages 35–74 using the European Standard. These
weighted averages for men and women are themselves averaged at the IMDQ level. Error bars are 95 % confidence intervals based on probabilistic
sensitivity analysis
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among 35–44 and 65–74. This demonstrates that
among younger men even a small reduction in CHD
mortality can lead to a substantial gain in life years.
This holds across all deprivation quintiles. Among
women, most of the gain in life years is at ages 55–
64 and 65–74. The CHD mortality at ages 35–44 and
45–54 is too low among women for there to be sub-
stantial improvement except among the most deprived
(Table 3).
Discussion
We modelled the effect that fully implementing all ele-
ments of the TCS would have on smoking prevalence in
England and how the resultant changes might vary by
socioeconomic circumstance. Improving all smoking
policies to achieve a maximum score on the TCS might
reduce smoking prevalence in England by approximately
15 % in relative terms among adults ages 35–74, and
even more in the most deprived socioeconomic quin-
tiles. There would be over 3000 fewer premature CHD
deaths with the biggest benefits in the most deprived
groups.
Reassuringly, our estimated smoking prevalence reduc-
tion attributable to the modelled tobacco control policies
seems similar to estimates from a recent study using
SimSmoke (~15 % versus ~17 % of relative reduction)
[39]. Unfortunately, direct comparison of IMPACT and
SimSmoke on avoidable deaths is not possible, because
SimSmoke estimates deaths from any smoke-attributed
disease rather than CHD specifically.
We estimated that an excise tax increase that in-
creased pack price by 20 % would contribute about half
of the total reduction in smoking prevalence. This in-
crease is feasible, considering the price of tobacco has
increased by more than 80 % over the last ten years [2].
Excise tax increases are generally considered the most
immediate and effective path to quitting [40]. In reality,
evidence suggest that the more deprived are more sensi-
tive to price change and reduce consumption more than
the less deprived [18–20], rendering tobacco price
policies the most equitable option for tobacco control
[12]. In addition, the increased tax revenue may be
redistributed to the less well-off through targeted smok-
ing cessation and other health promotion programmes,
further increasing the equity of this policy.
The TCS is based on a comprehensive, multi-pronged
approach to tobacco control and measures three key
areas: accessibility, affordability, and acceptability. It is
generally agreed that comprehensive approaches to to-
bacco control work best because they lower initiation,
increase cessation and reduce consumption [8, 41]. The
TCS score across countries has been shown to be posi-
tively correlated with quit attempts [42]. TCS is there-
fore a useful metric when focussing on adult smoking
prevalence, as we have done. Most of the policy categor-
ies would also counteract youth initiation of smoking,
but different effect sizes and SEC gradients might be
needed.
Despite the usefulness of TCS score for policy analysis
and relative intra-country comparisons a TCS of 100
does not mean that there is no further room for im-
provement. This is especially true for countries already
scoring high in the TCS, like UK. A typical example is
policies on tobacco price, where UK has the highest in
Europe; yet it can increase even further depending on
political will, achieving a score higher than 100. There-
fore, our decision to model the optimum TCS score is
based on the possible usefulness for policy makers rather
than an ultimate goal for UK tobacco control policy.
Stricter smoking policies have already contributed to
rapid improvements in cardiovascular health in the UK
[43, 44] and have reduced health inequalities in Ireland
[45]. CHD and other vascular diseases can show rapid
improvements in mortality due to risk factor changes
[46]. We demonstrated that declines in smoking preva-
lence would lower premature CHD mortality and that
the most disadvantaged socioeconomic groups would
benefit most. This would reduce absolute inequality of
premature CHD mortality. Many other tobacco related
cancers and other non-communicable diseases would
also benefit from smoking cessation, though the time lag
between risk factor change and mortality improvement
may not be as immediate.
Improvements in the policies we assessed would
make a dent in current adult smoking prevalence in
England, but further policy initiatives could have add-
itional impacts and would be required to begin talk of a
“Tobacco End Game” [47, 48]. Recent research suggests
that e-cigarettes might help with smoking cessation in
the short-term but not in the long-term, although fur-
ther research is needed [49, 50]. A ban on smoking in
cars due to be implemented in England on 1st October
2015 could lead to more people declaring their homes
smoke-free [51], which itself might enable quit attempts
[52]. Small trials of financial incentives for pregnant
women to stop smoking appear promising [53]. The
government has also recently consulted on the possibil-
ity of a minimum excise tax and a levy on tobacco com-
panies [54], both of which could raise prices further
and, in the case of the former, help narrow inequalities
in smoking by closing the price gap between cheap and
expensive cigarettes [55]. When the tobacco purchase
age was raised from 16 to 18 in England, smoking
prevalence declined dramatically among 16–17 year
olds [56]. Further raising the tobacco purchase age, as
currently in place or under consideration in parts of
the US, might accelerate long-term reductions [57, 58].
Finally, various more innovative options including ‘very
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Table 3 Absolute reduction in smoking prevalence, CHD deaths prevented or postponed (DPP), and Life years gained (LYG)
Absolute reduction in smoking prevalence CHD DPP LYG from DPP
Men IMDQ1 Ages 35–44 2.0 % (0.9–3.3 %) 10 (5–20) 400 (200–600)
Ages 45–54 1.8 % (0.8–2.9 %) 40 (30–60) 800 (600–1300)
Ages 55–64 1.4 % (0.5–2.5 %) 70 (50–110) 1100 (800–1600)
Ages 65–74 1.0 % (0.1–2.0 %) 60 (40–90) 300 (200–500)
IMDQ2 Ages 35–44 2.9 % (1.7–4.2 %) 20 (10–30) 700 (400–1000)
Ages 45–54 2.3 % (1.2–3.4 %) 60 (50–80) 1300 (1000–1800)
Ages 55–64 1.8 % (0.7–2.9 %) 110 (80–140) 1600 (1200–2100)
Ages 65–74 1.3 % (0.3–2.4 %) 100 (70–140) 600 (400–800)
IMDQ3 Ages 35–44 3.5 % (2.2–4.8 %) 30 (20–40) 800 (500–1200)
Ages 45–54 3.0 % (1.8–4.3 %) 90 (70–130) 2000 (1400–2700)
Ages 55–64 2.7 % (1.4–4.0 %) 190 (130–260) 2700 (1900–3700)
Ages 65–74 1.5 % (0.4–2.6 %) 130 (90–190) 800 (500–1200)
IMDQ4 Ages 35–44 4.3 % (2.7–5.6 %) 40 (20–50) 1100 (700–1700)
Ages 45–54 3.9 % (2.4–5.3 %) 130 (100–170) 2800 (2000–3700)
Ages 55–64 3.2 % (1.6–4.6 %) 240 (180–340) 3500 (2500–4800)
Ages 65–74 2.6 % (0.9–4.1 %) 220 (150–310) 1500 (900–2400)
IMDQ5 Ages 35–44 5.5 % (3.3–7.2 %) 50 (30–70) 1500 (900–2100)
Ages 45–54 5.4 % (3.2–7.2 %) 180 (130–240) 3800 (2600–4900)
Ages 55–64 4.9 % (2.6–6.8 %) 360 (250–470) 4900 (3400–6400)
Ages 65–74 3.7 % (1.5–5.6 %) 300 (200–420) 2000 (1200–3500)
Women IMDQ1 Ages 35–44 1.5 % (0.5–2.5 %) 1 (0–2) 30 (0–80)
Ages 45–54 1.4 % (0.5–2.3 %) 6 (4–9) 160 (100–240)
Ages 55–64 1.2 % (0.3–2.2 %) 20 (10–30) 340 (230–520)
Ages 65–74 0.9 % (0.1–1.8 %) 25 (20–40) 600 (400–800)
IMDQ2 Ages 35–44 2.1 % (1.0–3.1 %) 1 (0–3) 50 (0–100)
Ages 45–54 1.9 % (0.9–2.8 %) 8 (6–12) 230 (170–340)
Ages 55–64 1.7 % (0.7–2.8 %) 30 (20–40) 600 (400–800)
Ages 65–74 1.1 % (0.2–2.0 %) 40 (30–60) 900 (600–1300)
IMDQ3 Ages 35–44 2.7 % (1.5–3.8 %) 3(0–7) 100 (0–300)
Ages 45–54 2.5 % (1.4–3.6 %) 15(10–25) 400 (300–600)
Ages 55–64 2.3 % (1.1–3.4 %) 50(30–70) 900 (600–1300)
Ages 65–74 1.4 % (0.4–2.4 %) 60(40–90) 1200 (800–1700)
IMDQ4 Ages 35–44 3.3 % (1.9–4.5 %) 6 (0–13) 200 (0–500)
Ages 45–54 3.4 % (1.9–4.6 %) 30 (20–50) 900 (500–1400)
Ages 55–64 2.9 % (1.4–4.2 %) 90 (60–140) 1700 (1100–2700)
Ages 65–74 2.1 % (0.7–3.5 %) 120 (80–190) 1900 (1300–2700)
IMDQ5 Ages 35–44 4.2 % (2.3–5.8 %) 10 (0–30) 500 (0–1000)
Ages 45–54 4.6 % (2.6–6.3 %) 60 (40–100) 1600 (900–2700)
Ages 55–64 4.1 % (2.0–5.8 %) 130 (80–220) 2500 (1400–4200)
Ages 65–74 3.2 % (1.2–4.9 %) 170 (100–290) 2600 (1700–3600)
Stratified by age group, sex, and quintiles of Index of Multiple Deprivation (IMDQ, 1 = least deprived, 5 =most deprived). 95 % confidence intervals from probabilistic
sensitivity analysis
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low nicotine content’ (VLNC) cigarettes sold at a lower
price than standard cigarettes could play a role in fur-
ther reducing tobacco use [59]. Yet, challenges lay
ahead. The observed and forthcoming reductions in
funding for mass media campaigns and smoking cessa-
tion services may have detrimental effects on tobacco
control and postpone the ‘end game’ further in the fu-
ture [25, 60].
Strengths
Modelling studies of this type are rarely stratified by so-
cioeconomic circumstance, and none has yet done so for
England. We used four key systematic reviews [9–12] to
derive information about SEC gradients in effectiveness
of tobacco control policies. We reviewed many of the
studies cited by these four systematic reviews and ac-
tively checked for newer studies.
We linked declines in smoking prevalence to declines
in CHD mortality, using a model validated by SEC for
England [14]. The smoking prevalence reported by ONS
was stratified into the same strata (IMDQ, age, sex) as
the CHD mortality, thus no additional assumptions were
necessary to link the two.
Limitations
We focussed only on adult smoking prevalence, reduc-
tions in CHD and used a short time-frame. The long-term
effects might be about twice as large when considering re-
duced youth initiation [39] and greater still, when consid-
ering other tobacco related diseases and environmental
tobacco smoking.
Despite our effort to identify the best available sources
to inform our model, there is a lack of strong evidence
regarding the existence and quantification of the socio-
economic gradient for the effect of some of the modelled
policies. This is also true for the combined effect of the
interventions. We assumed multiplicative effects of the
combined modelled policies, given the lack of evidence
to support any functional form for the combined effect.
Moreover, in our study we ignored the rise in e-
cigarettes use, a potentially important emerging trend.
Unfortunately, none of the data sources used to inform
IMPACT considered e-cigarettes specifically, and their
overall impact on smokers and non-smokers is lacking
consistent evidence.
Finally, we did not consider implementation. Now that
many public health functions in England have a stronger
local element than before, there is greater likelihood of
inconsistent implementation.
Conclusions
A comprehensive improvement in tobacco control pol-
icies in England could have immediate, long-lasting ef-
fects. Health would improve substantially more among
those who stand to gain the most, thus narrowing
health-related inequalities. Further research is needed to
explore the equity of specific tobacco control policies
and to identify their optimal mixture to maximise effi-
ciency and equity; particularly considering the challenges
that ongoing cuts in Public Health funding across Eng-
land pose to communities.
Additional file
Additional file 1: Technical Appendix. (DOCX 36 kb)
Competing interests
All authors have completed the ICMJE uniform disclosure form at
www.icmje.org/coi_disclosure.pdf (available on request from the corresponding
author) and declare: no support from any organisation for the submitted work;
no financial relationships with any organisations that might have an interest in
the submitted work in the previous three years; no other relationships or
activities that could appear to have influenced the submitted work.
Authors’ contributions
KA, SC and MOF developed the idea. KA designed the analysis. KA, CK LH
contributed to the analysis. AG contributed with tobacco policy issues. MW
contributed with equity aspects. PD supervised statistical analyses. All authors
commented on versions of the manuscript for key intellectual content and
approved the final version of the manuscript. MOF is the guarantor.
Acknowledgments
We would like to acknowledge the development of the original IMPACT SEC
model. The English SEC project was conducted by M Bajekal and S Scholes.
H Hande set up the worksheet template; S Scholes populated the model
and was its custodian; M Bajekal ensured the integrity of inputs & outputs
and provided SEC-related methodological solutions. M O’Flaherty & N
Hawkins provided support, clinical expertise and generated the therapeutic
input. The UCL team was led by R Raine, and S Capewell co-ordinated the
overall project.
Funding
This article presents independent research funded by the National Institute
for Health Research’s School for Public Health Research (NIHR SPHR). The
SPHR is funded by the National Institute for Health Research (NIHR). SPHR is
a partnership between the Universities of Sheffield, Bristol, Cambridge,
Exeter, UCL; The London School for Hygiene and Tropical Medicine; the
LiLaC collaboration between the Universities of Liverpool and Lancaster and
Fuse; The Centre for Translational Research in Public Health, a collaboration
between Newcastle, Durham, Northumbria, Sunderland and Teesside
Universities. The views expressed are those of the author(s) and not
necessarily those of the NHS, the NIHR or the Department of Health. The
funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Author details
1Lancaster Medical School, Lancaster University, Lancaster, UK. 2Department
of Public Health & Policy, University of Liverpool, Liverpool, UK. 3Department
for Health, University of Bath, UK Centre for Tobacco and Alcohol Studies
(UKCTAS), Bath, UK.
Received: 30 August 2015 Accepted: 15 March 2016
References
1. Opinions and lifestyle survey, adult smoking habits in Great Britain, 2013.
[http://www.ons.gov.uk/ons/rel/ghs/opinions-and-lifestyle-survey/adult-
smoking-habits-in-great-britain–2013/index.html]. Accessed 03 Aug 2015.
2. Statistics on smoking: England 2014 [http://www.hscic.gov.uk/catalogue/
PUB14988].Accessed 03 Aug 2015.
Allen et al. BMC Public Health  (2016) 16:292 Page 8 of 10
3. Hiscock R, Bauld L, Amos A, Platt S. Smoking and socioeconomic status in
England: the rise of the never smoker and the disadvantaged smoker. J
Public Health Oxf Engl. 2012;34:390–6.
4. Giesinger I, Goldblatt P, Howden-Chapman P, Marmot M, Kuh D, Brunner E.
Association of socioeconomic position with smoking and mortality: the
contribution of early life circumstances in the 1946 birth cohort. J Epidemiol
Community Health. 2014;68:275–9.
5. Action on Smoking and Health (ASH). Smoking statistics: illness and death.
London: ASH; 2014.
6. Nabi H, Estaqiuo C, Auleley G-R. Smoking and mortality–beyond established
causes. N Engl J Med. 2015;372:2169.
7. Joossens L, Raw M. The tobacco control scale 2013 in Europe. In: Sixth
European Conference on Tobacco or Health-ECToH, Istanbul, Turkey. 2014.
8. World Health Organization, others. WHO Report on the Global Tobacco
Epidemic, 2013: Enforcing Bans on Tobacco Advertising, Promotion and
Sponsorship. Geneva: World Health Organization; 2013.
9. Thomas S, Fayter D, Misso K, Ogilvie D, Petticrew M, Sowden A, Whitehead
M, Worthy G. Population tobacco control interventions and their effects on
social inequalities in smoking: systematic review. Tob Control. 2008;17:230–
7.
10. Hill S, Amos A, Clifford D, Platt S. Impact of tobacco control interventions
on socioeconomic inequalities in smoking: review of the evidence. Tob
Control. 2014;23:e89–97.
11. Brown T, Platt S, Amos A. Equity impact of European individual-level
smoking cessation interventions to reduce smoking in adults: a systematic
review. Eur J Public Health. 2014;24:551–6.
12. Brown T, Platt S, Amos A. Equity impact of population-level interventions
and policies to reduce smoking in adults: A systematic review. Drug Alcohol
Depend. 2014;138:7–16.
13. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart
disease mortality in England and Wales between 1981 and 2000. Circulation.
2004;109:1101–7.
14. Bajekal M, Scholes S, Love H, Hawkins N, O’Flaherty M, Raine R, Capewell S.
Analysing recent socioeconomic trends in coronary heart disease mortality
in England, 2000–2007: a population modelling study. PLoS Med. 2012;9:
e1001237.
15. Bandosz P, Aspelund T, Basak P, Bennett K, Bjorck L, Bruthans J, Guzman-
Castillo M, Hughes J, Hotchkiss J, Kabir Z, Laatikainen T, Leyland A,
O’Flaherty M, Palmieri L, Rosengren A, Bjork R, Vartiainen E, Zdrojewski T,
Capewell S, Critchley J. OP72 EUROHEART II - comparing policies to reduce
future coronary heart disease mortality in nine European countries:
modelling study. J Epidemiol Community Health. 2014;68 Suppl 1:A36.
16. Do smoking rates vary between more and less advantaged areas? [http://
www.ons.gov.uk/ons/rel/disability-and-health-measurement/do-smoking-rates-
vary-between-more-and-less-advantaged-areas-/2012/sty-smoking-rates.html].
Accessed 03 Aug 2015
17. McLennan D, Barnes H, Noble M, Davies J, Garratt E, Dibben C. The English
Indices of Deprivation 2010. 2011.
18. Townsend J. Price and consumption of tobacco. Br Med Bull. 1996;52:132–42.
19. Reed H. The Effects of Increasing Tobacco Taxation: A Cost Benefit and
Public Finances Analysis. London: Action on Smoking & Health; 2010.
20. International Agency for Research on Cancer. IARC Handbooks of
Cancer Prevention, Tobacco Control, Vol. 14: Effectiveness of Tax and
Price Policies for Tobacco Control. Lyon: International Agency for
Research on Cancer; 2011.
21. Levy DT, Currie L, Clancy L. Tobacco control policy in the UK: blueprint for
the rest of Europe? Eur J Public Health. 2013;23:201–6.
22. Nagelhout GE, Levy DT, Blackman K, Currie L, Clancy L, Willemsen MC. The
effect of tobacco control policies on smoking prevalence and smoking-
attributable deaths. Findings from the Netherlands SimSmoke Tobacco Control
Policy Simulation Model. Addict Abingdon Engl. 2012;107:407–16.
23. Fichtenberg CM, Glantz SA. Effect of smoke-free workplaces on smoking
behaviour: systematic review. BMJ. 2002;325:188.
24. Langley T, Szatkowski L, Lewis S, McNeill A, Gilmore AB, Salway R, Sims M.
The freeze on mass media campaigns in England: a natural experiment of
the impact of tobacco control campaigns on quitting behaviour. Addict
Abingdon Engl. 2014;109:995–1002.
25. Action on Smoking and Health (ASH). ASH Briefing: UK tobacco control
policy and expenditure. London: ASH; 2014.
26. Levy DT, Friend K. A computer simulation model of mass media interventions
directed at tobacco use. Prev Med. 2001;32:284–94.
27. Sims M, Salway R, Langley T, Lewis S, McNeill A, Szatkowski L, Gilmore AB.
Effectiveness of tobacco control television advertising in changing tobacco
use in England: a population-based cross-sectional study. Addict Abingdon
Engl. 2014;109:986–94.
28. Niederdeppe J, Kuang X, Crock B, Skelton A. Media campaigns to promote
smoking cessation among socioeconomically disadvantaged populations:
what do we know, what do we need to learn, and what should we do
now? Soc Sci Med 1982. 2008;67:1343–55.
29. Saffer H, Chaloupka F. Tobacco Advertising: Economic Theory and
International Evidence, Working Paper. Cambridge: National Bureau of
Economic Research; 1999.
30. Chaloupka FJ, Warner KE, Acemoğlu D, Gruber J, Laux F, Max W, Newhouse
J, Schelling T, Sindelar J. An evaluation of the FDA’s analysis of the costs
and benefits of the graphic warning label regulation. Tob Control. 2015;24:
112–9.
31. UK first EU country to adopt plain packaging for cigarettes [http://www.
euractiv.com/sections/health-consumers/uk-first-eu-country-adopt-plain-
packaging-cigarettes-312960]. Accessed 03 Aug 2015
32. Durkin S, Brennan E, Coomber K, Zacher M, Scollo M, Wakefield M. Short-
term changes in quitting-related cognitions and behaviours after the
implementation of plain packaging with larger health warnings: findings
from a national cohort study with Australian adult smokers. Tob Control.
2015;24 Suppl 2:ii26–32.
33. British Heart Foundation. Standardised Packaging for Tobacco Products:
Recent Evidence from Australia and United Kingdom. London: British Heart
Foundation; 2014.
34. Pechey R, Spiegelhalter D, Marteau TM. Impact of plain packaging of
tobacco products on smoking in adults and children: an elicitation of
international experts’ estimates. BMC Public Health. 2013;13:18.
35. Swift E, Borland R, Cummings KM, Fong GT, McNeill A, Hammond D,
Thrasher JF, Partos TR, Yong H-H. Australian smokers’ support for plain or
standardised packs before and after implementation: findings from the ITC
Four Country Survey. Tob Control. 2014;24:616–21.
36. Bauld L, Judge K, Platt S. Assessing the impact of smoking cessation services
on reducing health inequalities in England: observational study. Tob
Control. 2007;16:400–4.
37. Guzman Castillo M, Gillespie DOS, Allen K, Bandosz P, Schmid V, Capewell S,
O’Flaherty M. Future declines of coronary heart disease mortality in England
and Wales could counter the burden of population ageing. PloS One. 2014;9:
e99482.
38. Schmid VJ, Held L. Bayesian age-period-cohort modeling and prediction-BAMP.
J Stat Softw. 2007;21:1–15.
39. Levy DT, Huang A-T, Currie LM, Clancy L. The benefits from complying with
the framework convention on tobacco control: a SimSmoke analysis of 15
European nations. Health Policy Plan. 2014;29:1031–42.
40. Jha P, Peto R. Global effects of smoking, of quitting, and of taxing tobacco.
N Engl J Med. 2014;370:60–8.
41. Centers for Disease Control, (CDC) P, others. Best Practices for Comprehensive
Tobacco Control programs—2014. Atlanta: US Department of Health and
Human Services, Centers for Disease Control and Prevention, National Center
for Chronic Disease Prevention and Health Promotion, Office on Smoking and
Health; 2014.
42. Schaap MM, Kunst AE, Leinsalu M, Regidor E, Ekholm O, Dzurova D,
Helmert U, Klumbiene J, Santana P, Mackenbach JP. Effect of nationwide
tobacco control policies on smoking cessation in high and low educated
groups in 18 European countries. Tob Control. 2008;17:248–55.
43. Pell JP, Haw S, Cobbe S, Newby DE, Pell ACH, Fischbacher C, McConnachie
A, Pringle S, Murdoch D, Dunn F, Oldroyd K, Macintyre P, O’Rourke B,
Borland W. Smoke-free legislation and hospitalizations for acute coronary
syndrome. N Engl J Med. 2008;359:482–91.
44. Sims M, Maxwell R, Bauld L, Gilmore A. Short term impact of smoke-free
legislation in England: retrospective analysis of hospital admissions for
myocardial infarction. BMJ. 2010;340:c2161.
45. Stallings-Smith S, Goodman P, Kabir Z, Clancy L, Zeka A. Socioeconomic
differentials in the immediate mortality effects of the national Irish smoking
ban. PloS One. 2014;9:e98617.
46. Morita H, Ikeda H, Haramaki N, Eguchi H, Imaizumi T. Only two-week smoking
cessation improves platelet aggregability and intraplatelet redox imbalance of
long-term smokers. J Am Coll Cardiol. 2005;45:589–94.
47. van der Eijk Y. Development of an integrated tobacco endgame strategy.
Tob Control. 2015;24:336–40.
Allen et al. BMC Public Health  (2016) 16:292 Page 9 of 10
48. Warner KE. An endgame for tobacco? Tob Control. 2013;22 Suppl 1:i3–5.
49. Brose LS, Hitchman SC, Brown J, West R, McNeill A. Is the use of electronic
cigarettes while smoking associated with smoking cessation attempts,
cessation and reduced cigarette consumption? A survey with a 1-year
follow-up. Addict Abingdon Engl. 2015;110:1160–8.
50. Al-Delaimy WK, Myers MG, Leas EC, Strong DR, Hofstetter CR. E-cigarette use
in the past and quitting behavior in the future: a population-based study.
Am J Public Health. 2015;105:1213–9.
51. Murphy-Hoefer R, Madden P, Maines D, Coles C. Prevalence of smoke-free
car and home rules in Maine before and after passage of a smoke-free
vehicle law, 2007–2010. Prev Chronic Dis. 2014;11:130132.
52. Borland R, Yong H-H, Cummings KM, Hyland A, Anderson S, Fong GT.
Determinants and consequences of smoke-free homes: findings from the
International Tobacco Control (ITC) Four Country Survey. Tob Control. 2006;
15 Suppl 3:iii42–50.
53. Tappin D, Bauld L, Purves D, Boyd K, Sinclair L, MacAskill S, McKell J, Friel B,
McConnachie A, de Caestecker L, Tannahill C, Radley A, Coleman T,
Cessation in Pregnancy Incentives Trial Team. Financial incentives for
smoking cessation in pregnancy: randomised controlled trial. BMJ. 2015;350:
h134.
54. Minimum excise tax [https://www.gov.uk/government/consultations/
minimum-excise-tax/minimum-excise-tax]. Accessed 03 Aug 2015.
55. Gilmore AB, Tavakoly B, Taylor G, Reed H. Understanding tobacco industry
pricing strategy and whether it undermines tobacco tax policy: the example
of the UK cigarette market. Addict Abingdon Engl. 2013;108:1317–26.
56. Fidler JA, West R. Changes in smoking prevalence in 16-17-year-old versus
older adults following a rise in legal age of sale: findings from an English
population study. Addict Abingdon Engl. 2010;105:1984–8.
57. Steinberg MB, Delnevo CD. Increasing the “smoking age”: the right thing to
do. Ann Intern Med. 2013;159:558–9.
58. Bonnie RJ, Alberg AJ, Nola RB, Caulkins J, Halpern-Felsher B, Jett S, Juster H,
Klein JD, Lantz PM, Mermelstein R, Meza R, O’Malley P, Thompson K. Public
Health Implications of Rising the Minimum Age of Legal Access to Tobacco
Products. Washington, DC: Institute of Medicine; 2015.
59. Walker N, Fraser T, Howe C, Laugesen M, Truman P, Parag V, Glover M,
Bullen C. Abrupt nicotine reduction as an endgame policy: a randomised
trial. Tob Control. 2014;24:e251–57.
60. Lacobucci G. Public health—the frontline cuts begin. BMJ. 2016;352:i272.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Allen et al. BMC Public Health  (2016) 16:292 Page 10 of 10
